Price T Rowe Associates Inc. MD Invests $45,000 in Design Therapeutics, Inc. (NASDAQ:DSGN)

Price T Rowe Associates Inc. MD acquired a new stake in Design Therapeutics, Inc. (NASDAQ:DSGN) in the 1st quarter, Holdings Channel reports. The firm acquired 11,147 shares of the company’s stock, valued at approximately $45,000.

Other hedge funds also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in Design Therapeutics by 30.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 21,503 shares of the company’s stock valued at $57,000 after purchasing an additional 4,983 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Design Therapeutics by 317.6% during the fourth quarter. Federated Hermes Inc. now owns 11,999 shares of the company’s stock valued at $32,000 after buying an additional 9,126 shares during the last quarter. Pale Fire Capital SE bought a new stake in shares of Design Therapeutics in the fourth quarter valued at about $28,000. Bleakley Financial Group LLC acquired a new stake in Design Therapeutics during the first quarter worth about $46,000. Finally, Simplicity Wealth LLC acquired a new stake in Design Therapeutics during the first quarter worth about $46,000. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Stock Performance

Shares of Design Therapeutics stock opened at $4.45 on Monday. The firm has a market cap of $251.40 million, a P/E ratio of -4.24 and a beta of 1.83. The firm’s 50-day simple moving average is $4.02 and its 200-day simple moving average is $3.66. Design Therapeutics, Inc. has a twelve month low of $1.94 and a twelve month high of $5.27.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. On average, equities analysts forecast that Design Therapeutics, Inc. will post -1.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on DSGN shares. Piper Sandler raised Design Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $6.00 to $12.00 in a report on Tuesday, May 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a research note on Tuesday, August 6th.

Insider Activity at Design Therapeutics

In other Design Therapeutics news, Director Arsani William sold 814,874 shares of the stock in a transaction on Friday, August 9th. The stock was sold at an average price of $4.25, for a total transaction of $3,463,214.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 31.20% of the stock is owned by insiders.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.